GSK vs Moderna
GSK (GSK), health care, and Moderna (MRNA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
GSK is worth $99.1B on the stock market and Moderna $83.9B: GSK is valued at 18% more. GSK's operating margin in its latest fiscal year was 24.3% and Moderna's -158%. Over the past year GSK's share price has moved +6.42% and Moderna's +764%.
Key facts
- GSK market value
- $99.1B
- Moderna market value
- $83.9B
- GSK P/E
- 17.2
- GSK revenue
- $43.4BFY to 2025-12-31
- Moderna revenue
- $1.9BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | GSK | Moderna |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $99.1Bhigher | $83.9Blower |
| Revenue | $43.4Bhigher | $1.9Blower |
| Earnings | $7.6Bhigher | -$2.8Blower |
| Employees | 66,841higher | 4,700lower |
| Total assets | $81.1Bhigher | $12.3Blower |
| Valuation | ||
| P/E | 17.2 | — |
| P/S | 2.3lower | 43.2higher |
| P/B | — | 12.3 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 24.3%higher | -158%lower |
| Balance sheet | ||
| Net assets | $21.7Bhigher | $8.7Blower |
| Total liabilities | $59.9Bhigher | $3.7Blower |
| Total debt | $19.2Bhigher | $590Mlower |
| Cash on hand | $4.5Bhigher | $2.6Blower |
| Price change | ||
| Today | -1.90%higher | -3.65%lower |
| 1 year | +6.42%lower | +764%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
GSK only (11)
- Dodge & Cox team1.1%
- Thomas Kahn0.9%
- Primecap team0.8%
- Charles Brandes (founder)0.5%
- Ken Fisher0.5%
- Jeremy Grantham (co-founder)0.4%
- Tweedy, Browne team0.3%
- Steve Cohen0.2%
- Howard Gleicher0.1%
- Murray Stahl<0.1%
- Richard Pzena<0.1%
Moderna only (2)
- Baillie Gifford team2.1%
- Ron Baron0.4%
Percentages are each holding's share of that investor's reported portfolio. Who owns GSK · Who owns MRNA
More on GSK
Further comparisons
GSK against its closest peers
Moderna against its closest peers
Learn
Questions and answers
Which is bigger, GSK or Moderna?
By market value, GSK is the larger: $99.1B against $83.9B for Moderna. By revenue in its latest fiscal year, GSK is the larger: $43.4B against $1.9B for Moderna.
Which has the higher operating margin?
GSK: 24.3%, against -158% for Moderna. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
GSK: $19.2B, against $590M for Moderna. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both GSK and Moderna?
None of the tracked superinvestors holds both in their latest 13F filing. 11 hold GSK and 2 hold Moderna.
Cite this page
Funkfolio, “GSK vs Moderna”, data as of 17 November 2026. https://funkfolio.com/compare/gsk-vs-mrna
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.